Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Toxic myopathies.

Ronan J Walsh1, Anthony A Amato

  • 1Neuromuscular Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA. rjwalsh@partners.org

Neurologic Clinics
|March 11, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idiopathic Inflammatory Myopathies.

Continuum (Minneapolis, Minn.)·2025
Same author

Item selection for the development and validation of a revised classification criteria for adult and juvenile idiopathic inflammatory myopathies: MyoROC project.

Seminars in arthritis and rheumatism·2025
Same author

Andrew G. Engel (1930-2024).

Neurology·2025
Same author

Effectiveness and Safety of IVIG for the Treatment of HMGCR Immune-Mediated Necrotizing Myopathy.

Muscle & nerve·2024
Same author

Investigating phenotypic variability patterns in myotonic dystrophy type 2 in a neuromuscular referral center retrospective cohort.

Neuromuscular disorders : NMD·2024
Same author

Aggregating the Loose Threads.

The New England journal of medicine·2024

Early recognition of toxic myopathies is crucial for potential recovery. Promptly removing the causative drug or toxin improves the chances of full muscle function restoration.

Area of Science:

  • Pharmacology
  • Toxicology
  • Neurology

Background:

  • Muscle tissue's high metabolic activity makes it susceptible to drug and toxin-induced damage.
  • Toxic myopathies can manifest with a spectrum of symptoms, from mild pain to severe muscle breakdown (rhabdomyolysis) and organ failure.
  • Understanding the multifactorial pathogenic bases is key to managing these conditions.

Purpose of the Study:

  • To review drugs commonly causing toxic myopathies.
  • To detail the clinical and histopathologic features of drug-induced myopathies.
  • To illustrate potential cellular mechanisms underlying toxic myopathies.

Main Methods:

  • Literature review of drugs associated with toxic myopathy.
  • Analysis of clinical presentations and histopathologic findings.

Related Experiment Videos

  • Exploration of cellular pathways affected by myotoxic agents.

    • Main Results:

    • Identified key drugs implicated in toxic myopathies.
    • Described characteristic clinical and histopathologic manifestations.
    • Provided insights into the cellular mechanisms of muscle injury.

    Conclusions:

    • Early identification and removal of offending agents are vital for favorable outcomes in toxic myopathies.
    • Diverse drugs can induce myotoxicity through various cellular disruptions.
    • Further research into cellular mechanisms can guide therapeutic strategies.